Raptor Inc.'s preclinical programs target cancer, neurodegenerative disorders and infectious diseases. HepTide(TM) is designed to utilize engineered RAP-based peptides conjugated to drugs to target their delivery to the liver to potentially treat primary liver cancer and hepatitis. In neurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) are currently undergoing evaluation at Stanford University in cell culture and preclinical models for their ability to enhance the transport of molecules from blood to brain. In an effort to protect its novel approach, Raptor Inc. currently has five patent applications in review in the U.S., and countries in Europe and Asia, as well as two provisional patent applications licensed from Washington University. In addition, Raptor Inc. has submitted two new provisional patent applications in the U.S., the first of which covers a new family of RAP peptides, and the second application to further support and expand its coverage in specific disease indications.
Bennu executes the clinical development of internal product candidates
and in-licensed candidates that are: 1) new chemical entities in
mid-to-late stage clinical development; 2) currently approved drugs with
potential efficacy in additional indications; and 3) treatments that Bennu
could repurpose or reformulate as potentially more effective or convenient
treatments for their currently approved indications. Bennu's initial
clinical programs include the treatment of aldeh
|SOURCE Raptor Pharmaceuticals Corp.|
Copyright©2008 PR Newswire.
All rights reserved